Breakeven Date Change • Jun 30
Forecast to breakeven in 2029 The 4 analysts covering PYC Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$77.9m in 2029. Average annual earnings growth of 5.8% is required to achieve expected profit on schedule. Ankündigung • Jun 15
PYC Therapeutics Announces Company Secretary Changes, Effective June 15, 2026 PYC Therapeutics Limited advised that Mr. Stephen Ledger and Mr. Jonathan Riley had been appointed as joint Company Secretaries of the Company effective June 15, 2026. Mr. Ledger is an experienced Company Secretary who holds a Bachelor of Commerce from the University of Western Australia. He currently serves as a Non-Executive Director for Bertling Logistics Australia and ArcelorMittal Projects Australia, and is Founder and Executive Director of Ledger Financial Group. Mr. Riley is an experienced legal counsel who holds a Bachelor of Laws and Bachelor of Science (Pharmacology) from the University of Western Australia. Prior to joining PYC, Mr. Riley held a senior legal role at CSL Limited in Melbourne. For the purposes of ASX Listing Rule 12.6, Mr. Ledger will be responsible for communications with ASX in relation to Listing Rule matters. Mr. Daniel Coletta has resigned as Company Secretary effective June 15, 2026. Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • May 01
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Mar 10
PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million. PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 600 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 272,740,242
Price\Range: AUD 1.5
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 31,197,631
Price\Range: AUD 1.5
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 85,489,067
Price\Range: AUD 1.5
Discount Per Security: AUD 0.075
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,573,060
Price\Range: AUD 1.5
Discount Per Security: AUD 0.075
Transaction Features: Rights Offering; Subsequent Direct Listing Ankündigung • Feb 04
PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million. PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 128.233601 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 85,489,067
Price\Range: AUD 1.5
Discount Per Security: AUD 0.09
Transaction Features: Subsequent Direct Listing Board Change • Dec 24
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chair Peter Coleman was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Oct 18
PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025 PYC Therapeutics Limited, Annual General Meeting, Nov 18, 2025. Location: at the auditorium, the harry perkins institute of, medical research, qeii medical centre, 6 verdun street, nedlands, western australia Australia Ankündigung • Sep 22
Pyc Therapeutics Limited Announces Board Changes PYC Therapeutics Limited announced appointment of Professor Ian Jeffrey Constable effective 21 September 2025. cessation of Dr Rohan Hockings effective 16 September 2025, MICHAEL ROSENBLATT effective 21 September 2025, and JASON HADDOCK effective 21 September 2025 as Director. Ankündigung • Aug 30
PYC Therapeutics Limited Auditor Raises 'Going Concern' Doubt PYC Therapeutics Limited filed its Annual on Aug 28, 2025 for the period ending Jun 30, 2025. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Board Change • Aug 18
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board Marc Pennesi was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Breakeven Date Change • Aug 18
Forecast to breakeven in 2028 The 5 analysts covering PYC Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$129.9m in 2028. Average annual earnings growth of 24% is required to achieve expected profit on schedule. Ankündigung • Apr 10
PYC Therapeutics Limited Announces First Subject in Phase 1A Single Ascending Dose (Sad) Study of PYC -003 PYC Therapeutics Limited announced that the first subject in a Phase 1a Single Ascending Dose (SAD) study of PYC-003 in healthy volunteers has been dosed with the drug candidate. The subject received a 0.4 mg/kg dose of PYC-003 intravenously. Seven additional healthy volunteers will receive either the drug candidate at the same dose or a placebo control over the coming weeks. A meeting of the Safety Review Committee (SRC) overseeing this clinical trial will occur in June/July4 to review the 4-week follow-up data from all subjects in this cohort and an anticipated request to escalate dosing in cohort 2 of the SAD to 1.2 mg/kg5. Part B of this Phase 1a study will evaluate the safety/tolerability and efficacy profile of PYC-003 in patients with PKD - this part of the trial is expected to commence in third quarter 20256. Parts A and B of the SAD will be followed by an Open-Label Extension (OLE) study facilitating repeat dosing and evaluation of the optimal dosing regimen of PYC-003 alongside a Phase 1b Multiple Ascending Dose (MAD) study to evaluate the safety/t tolerability and efficacy profile of PY-003. Ankündigung • Feb 18
PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million. PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 145.814913 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 116,651,930
Price\Range: AUD 1.25
Transaction Features: Rights Offering Board Change • Feb 04
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board Marc Pennesi was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Dec 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board David Birch was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Nov 15
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$88.7m (US$57.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$13m net loss in 3 years). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (AU$88.7m market cap, or US$57.3m). Ankündigung • Oct 14
PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024 PYC Therapeutics Limited, Annual General Meeting, Nov 13, 2024. Location: at the auditorium, the harry perkins institute of, medical research, qeii medical centre, 6 verdun street, nedlands, western australia Australia Board Change • Sep 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Ophthalmology Clinical Advisory Board David Birch was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Ankündigung • May 01
PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million. PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 499,999,999
Price\Range: AUD 0.08
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 168,509,482
Price\Range: AUD 0.08
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 70,600,000
Price\Range: AUD 0.08
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 194,106,793
Price\Range: AUD 0.08
Transaction Features: Regulation S; Rights Offering Breakeven Date Change • May 01
Forecast to breakeven in 2026 The 2 analysts covering PYC Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$14.1m in 2026. Average annual earnings growth of 38% is required to achieve expected profit on schedule. Ankündigung • Mar 14
PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million. PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.
Security Name: Ordianry Shares
Security Type: Common Stock
Securities Offered: 933,216,784
Price\Range: AUD 0.08
Transaction Features: Rights Offering New Risk • Nov 24
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$25m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$25m free cash flow). Earnings are forecast to decline by an average of 6.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$28m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding). Ankündigung • Nov 15
Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease PYC Therapeutics announced the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication. PYC-003 is the fourth program in the Company's development pipeline – joining three other first-in-class RNA drug candidates with disease-modifying potential currently progressing into or through human trials. PYC plans to accelerate PYC-003 into human trials following these results. An Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to enable the commencement of human trials for this drug candidate is planned for H2 2024. PYC-003 is expected to have an accelerated pathway through human trials due to the extent of the unmet patient need in PKD. A New Drug Application in support of this candidate could be submitted following two clinical trials rather than the conventional three. PKD is a monogenic disease (meaning that it is caused by a mutation in a single gene). Drugs targeting monogenic diseases have the highest likelihood of demonstrating efficacy in clinical trials[12] and lower probability of off-target safety issues. PKD affects 1 in every 1,000 people across the globe. There are currently no drugs available that address the underlying cause of the disease and approximately 50% of PKD patients will progress to end-stage renal failure by the age of 60. PKD is characterised by the formation of multiple fluid filled cysts throughout the kidney and, to a lesser extent, other organs. Progression of the cyst frequency and volume over time ultimately leads to destruction of the internal architecture and function of the kidney. The data demonstrating that PYC-003 is effective in 3D patient-derived cyst models complements existing data from animal models highlighting the ability of this drug candidate to reach the cells affected in PKD[14]. PYC's drug delivery platform has already demonstrated the ability to deliver an RNA therapy to the target cells affected by the disease in vivo in high concentration. Ankündigung • Oct 24
PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023 PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023, at 09:00 W. Australia Standard Time. Location: The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands Western Australia Australia Agenda: To consider annual report; to consider remuneration report; to consider re-Election of Dr Michael Rosenblatt; to consider re Approval of Long Term Incentive Plan; and to consider re-insertion of proportional takeover provisions. New Risk • Aug 31
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$26m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$21m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Ankündigung • Aug 12
PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program PYC Therapeutics Limited announced that the VP-001 program, the first investigational drug candidate designed to address Retinitis Pigmentosa type 11 (RP11) to progress to human trials, has received Fast Track designation from the US Food and Drug Administration (FDA). The Fast Track process is "designed to facilitate the development, and the review of drugs to treat serious conditions and fill an unmet medical need" with Fast Track status " often leading to earlier drug approval and access by patients". Benefits of the Fast Track designation include: Increased frequency of meetings with the FDA to discuss the drug's development plan; Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met; and The potential for a Rolling Review in support of a New Drug Application. PYC will utilise the Fast Track designation to work with the FDA on advancing this important drug program towards patients on an accelerated timeline. Recent Insider Transactions • Jun 29
Non-Executive Chair of the Board recently bought AU$85k worth of stock On the 26th of June, Alan Tribe bought around 2m shares on-market at roughly AU$0.053 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Alan has been a buyer over the last 12 months, purchasing a net total of AU$219k worth in shares. Ankündigung • Jun 01
Pyc Appoints Andrew Taylor as Joint Company Secretary PYC advises the appointment of the company's Chief Financial Officer Mr. Andrew Taylor as joint Company Secretary effective immediately. Andrew is a chartered accountant and holds a Bachelor of Commerce degree from theUniversity of Western Australia and a Graduate Diploma of Applied Finance. He has over 13 years' experience in big 4 and ASX listed companies with international operations. Ankündigung • Feb 03
PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration PYC Therapeutics Limited announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) in support of its lead drug candidate known as VP-001. The FDA has a period of 30 days to review an IND application. In the event the IND is accepted, VP-001 will be the first investigational drug candidate with the potential to modify the course of Retinitis Pigmentosa type 11 to progress into clinical trials. Board Change • Nov 17
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Judy Lieberman is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • Aug 09
Non-Executive Chair of the Board recently bought AU$103k worth of stock On the 3rd of August, Alan Tribe bought around 2m shares on-market at roughly AU$0.061 per share. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months. Board Change • Apr 27
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Judy Lieberman is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • Feb 20
Non-Executive Chair of the Board recently bought AU$81k worth of stock On the 17th of February, Alan Tribe bought around 600k shares on-market at roughly AU$0.14 per share. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months. 
